Seer SEER
NASDAQ SEER
$1.95 +0.01 (+0.63%)
As of: Sep 4, 2026 · 2:54 PM EDT

Seer (SEER) Non-Current Deffered Revenue (2020 - 2021)

Seer (SEER) posted quarterly Non-Current Deffered Revenue of $2.7 million for Q3 2021, up 19.53% quarter-over-quarter from $2.2 million in Q2 2021.

Analysis

Seer (SEER) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends

Seer's Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $2.7 million for Q3 2021.

  • In Q3 2021, Non-Current Deffered Revenue changed N/A year-over-year to $2.7 million; the TTM figure through Sep 2021 stood at $2.7 million (changed N/A YoY), while the FY2020 annual figure was $1.9 million, changed N/A from the prior year.
  • Non-Current Deffered Revenue for Q3 2021 stood at $2.7 million, up from $2.2 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $2.7 million in Q3 2021, with the low at $1.9 million in Q1 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Vertex Pharmaceuticals 138.43 Bn 130.58 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 220.40 Mn
3 Argenx Se 63.34 Bn 58.15 Bn 1.37 Bn -
4 Moderna 57.98 Bn 52.85 Bn 52.00 Mn 147.00 Mn
5 Revolution Medicines 43.98 Bn 43.98 Bn - -
6 BeOne Medicines 39.92 Bn 34.82 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.42 Bn 32.11 Bn 992.69 Mn -
8 Royalty Pharma 28.42 Bn 27.58 Bn - -
9 Insmed 27.36 Bn 26.20 Bn 358.27 Mn -
10 Seer 107.70 Mn 107.70 Mn 1.51 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2021 2.69 Mn
Jun 30, 2021 2.25 Mn
Mar 31, 2021 1.88 Mn
Dec 31, 2020 1.90 Mn